Key points are not available for this paper at this time.
The novel antimuscarinic agent imidafenacin at a dose of 0.1 mg twice daily was not inferior to propiverine for the reduction of incontinence episodes, and well tolerated for the treatment of OAB symptoms.
Burchardt et al. (Mon,) studied this question.